Boehringer Ingelheim extended its restrictions on 340B drug sales to hospitals to Ofev, its expensive specialty drug for idiopathic pulmonary fibrosis.

Boehringer Ingelheim Extends 340B Contract Pharmacy Restrictions to Previously Exempt Specialty Drug Ofev

Drug manufacturer Boehringer Ingelheim (BI) this month extended its restrictions on 340B drug sales to hospitals to Ofev, its expensive specialty drug for idiopathic pulmonary fibrosis.

BI announced its new 340B pricing policy in late June. Effective Aug. 1, the company stopped shipping 340B-purchased drugs to hospitals’ contract pharmacies.

Drug manufacturer Boehringer Ingelheim (BI) this month extended its restrictions on 340B drug sales to hospitals to Ofev, its expensive specialty drug for idiopathic pulmonary fibrosis.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer